18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis

Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research

Related Links:

Abstract Neuromyelitis optica also known as Devic's syndrome is a rare autoimmune disorder that predominantly targets the optic nerves and the spinal cord. It is a debilitating disorder that damages a person's health. Initially it was considered as a variant of multiple sclerosis (MS). But, in 2004, a water channel protein associated antibody was found to be responsible for the disease. This helped in distinguishing the disease from multiple sclerosis. Multiple molecular mechanisms like complement dependent cytotoxicity, antibody‑dependent cellular cytotoxicity etc. contribute to the disease. Certain environment...
Source: Acta Neurobiologiae Experimentalis - Category: Neurology Authors: Tags: Acta Neurobiol Exp (Wars) Source Type: research
Authors: Kamal A, Hosny M, Abd Elwahab A, Shawki Kamal Y, Shehata HS, Hassan A Abstract BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). Aberrant expression of transcription factor forkhead box P3 (FoxP3) has been suggested to underlie different immunological disorders as FOXP3 expression is essential for T regulatory cells (Tregs) to maintain their suppressive and anti-inflammatory functions and exert immunologic self-tolerance. Interleukin-35 (IL-35) is an important immunosuppressive cytokine that is produced mainly by CD4+ FOXP3+ Tregs. OBJECTIVES: To a...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Publication date: November 2020Source: Multiple Sclerosis and Related Disorders, Volume 46Author(s): Xiaoyu Ma, Allan G. Kermode, Xueqiang Hu, Wei Qiu
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
(University of California - Riverside) Seema Tiwari-Woodruff a professor of biomedical sciences in the School of Medicine at UC Riverside, and her colleagues have received a grant of $373,000 from the National Multiple Sclerosis Society for a project in which her lab will select the five best candidate compounds to speed up nerve impulses, a promising new avenue to treat multiple sclerosis.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
tonio Uccelli Giuseppe Matarese Diego Centonze Francesca De Vito In multiple sclerosis (MS), activated T and B lymphocytes and microglial cells release various proinflammatory cytokines, promoting neuroinflammation and negatively affecting the course of the disease. The immune response homeostasis is crucially regulated by the activity of the enzyme adenosine deaminase (ADA), as evidenced in patients with genetic ADA deficiency and in those treated with cladribine tablets. We investigated in a group of patients with MS the associations of a single nucleotide polymorphism (SNP) of ADA gene with disease characteris...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
This review aims to describe two cases of Bal ò’s Concentric Sclerosis (BCS) and to review the state‐of‐the‐art literature. Through the analysis of current imaging practice, our purpose is to help clinicians reach early diagnosis, thus enhancing the chances of a more successful outcome for the patients. AbstractThe aim of this study was to describe two cases of Bal ó’s concentric sclerosis, and to review the state‐of‐the‐art literature. This dissertation is the result of a critical analysis matching the literature and our professional experience. Data were synthesized into a narrative ...
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: REVIEW ARTICLE Source Type: research
Adamantyl groups are key structural subunit commonly used in many marketed drugs targeting diseases ranging from viral infections to neurological disorders. The metabolic disposition of adamantyl compounds has been mostly studied using LC-MS based approaches. However, metabolite quantities isolated from biological preparations are often insufficient for unambiguous structural characterization by NMR. In this work, we utilized microcoil NMR in conjunction with LC-MS to characterize liver microsomal metabolites of an adamantyl based CB2 agonist AM9338, 1-(3-(1H-1,2,3-triazol-1-yl) propyl)-N-(adamantan-1-yl)-1H-indazole-3-car...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: November 2020Source: Multiple Sclerosis and Related Disorders, Volume 46Author(s): Paige Sutton, Flavius Raslau, Padmaja Sudhakar
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: November 2020Source: Multiple Sclerosis and Related Disorders, Volume 46Author(s): Noha A. Hashim, Nagwan A. Ismail, Engy Mohammed Emad
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Clinical Trials | Multiple Sclerosis | Nuclear Medicine